6α-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity
Journal of Medicinal Chemistry2002Vol. 45(17), pp. 3569–3572
Citations Over TimeTop 10% of 2002 papers
Roberto Pellicciari, Stefano Fiorucci, Emidio Camaioni, Carlo Clerici, Gabriele Costantino, Patrick Maloney, Antonio Morelli, Derek J. Parks, Timothy M. Willson
Abstract
A series of 6alpha-alkyl-substituted analogues of chenodeoxycholic acid (CDCA) were synthesized and evaluated as potential farnesoid X receptor (FXR) ligands. Among them, 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA) was shown to be a very potent and selective FXR agonist (EC(50) = 99 nM) and to be endowed with anticholeretic activity in an in vivo rat model of cholestasis.
Related Papers
- → 6α-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity(2002)725 cited
- → Role of farnesoid X receptor in cholestasis(2016)43 cited
- → Chenodeoxycholic Acid-mediated Activation of the Farnesoid X Receptor Negatively Regulates Hydroxysteroid Sulfotransferase(2006)37 cited
- → Glutamine attenuates obstructive cholestasis in rats via farnesoid X receptor–mediated regulation of Bsep and Mrp2(2016)10 cited
- → Licraside as novel potent FXR agonist for relieving cholestasis: structure-based drug discovery and biological evaluation studies(2023)3 cited